{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:03:54Z","timestamp":1771275834543,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00203-025-04540-8","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T07:43:12Z","timestamp":1762933392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clostridium botulinum serotype B: microbial genetics, toxin biosynthesis, current applications, and future prospects"],"prefix":"10.1007","volume":"208","author":[{"given":"Aditi","family":"Kulshreshtha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sataditya","family":"Jana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Rana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azhar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"4540_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1526-4610.43.7s.3.x","volume":"43","author":"KR Aoki","year":"2003","unstructured":"Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43:9\u201315","journal-title":"Headache"},{"key":"4540_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","volume":"55","author":"A Apostolidis","year":"2009","unstructured":"Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100\u2013120","journal-title":"Eur Urol"},{"key":"4540_CR3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"SS Arnon","year":"2001","unstructured":"Arnon SS, Schechter R, Inglesby TV et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059\u20131070","journal-title":"JAMA"},{"key":"4540_CR4","first-page":"153","volume":"6","author":"BE Atabey","year":"2024","unstructured":"Atabey BE, K\u0131l\u0131n\u00e7 Y (2024) Clinical use of botulinum toxins in oral and maxillofacial surgery. Dent Med J-Rev 6:153\u2013166","journal-title":"Dent Med J-Rev"},{"key":"4540_CR5","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-022-01473-y","volume":"20","author":"S Babaie","year":"2022","unstructured":"Babaie S, Taghvimi A, Hong J-H et al (2022) Recent advances in pain management based on nanoparticle technologies. J Nanobiotechnol 20:290","journal-title":"J Nanobiotechnol"},{"key":"4540_CR6","first-page":"496","volume":"29","author":"L Baumann","year":"2003","unstructured":"Baumann L, Black L (2003) Botulinum toxin type B (Myobloc). Dermatol Surg 29:496\u2013500","journal-title":"Dermatol Surg"},{"key":"4540_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2003.11.001","volume":"22","author":"LS Baumann","year":"2004","unstructured":"Baumann LS, Halem ML (2004) Botulinum toxin-B and the management of hyperhidrosis. Clin Dermatol 22:60\u201365","journal-title":"Clin Dermatol"},{"key":"4540_CR8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","volume":"26","author":"R Benecke","year":"2012","unstructured":"Benecke R (2012) Clinical relevance of botulinum toxin immunogenicity. BioDrugs 26:e1\u2013e9","journal-title":"BioDrugs"},{"key":"4540_CR9","volume":"10","author":"BK Bowe","year":"2022","unstructured":"Bowe BK, Wentz TG, Gregg BM et al (2022) Genomic diversity, competition, and toxin production by group I and II Clostridium botulinum strains used in food challenge studies. Microorganisms 10:1895","journal-title":"Microorganisms"},{"key":"4540_CR10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH et al (1999) Safety and efficacy of neurobloc (botulinum toxin type B) in type A\u2013resistant cervical dystonia. Neurology 53:1431","journal-title":"Neurology"},{"key":"4540_CR11","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/gbe\/evu164","volume":"6","author":"AT Carter","year":"2014","unstructured":"Carter AT, Austin JW, Weedmark KA et al (2014) Three classes of plasmid (47\u201363 kb) carry the type B neurotoxin gene cluster of group II clostridium botulinum. Genome Biol Evol 6:2076\u20132087","journal-title":"Genome Biol Evol"},{"key":"4540_CR12","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.bbapap.2015.05.013","volume":"1854","author":"G Chellappan","year":"2015","unstructured":"Chellappan G, Kumar R, Santos E et al (2015) Structural and functional analysis of botulinum neurotoxin subunits for pH-dependent membrane channel formation and translocation. Biochimica et Biophysica Acta (BBA) 1854:1510\u20131516","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"4540_CR13","first-page":"12509","volume":"34","author":"D Coraci","year":"2024","unstructured":"Coraci D, Maccarone MC, Ragazzo L et al (2024) Botulinum toxin in the rehabilitation of painful syndromes: multiperspective literature analysis, lexical analysis and systematic review of randomized controlled trials. Eur J Transl Myol 34:12509","journal-title":"Eur J Transl Myol"},{"key":"4540_CR14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00415-008-0738-5","volume":"255","author":"J Costa","year":"2008","unstructured":"Costa J, Rocha ML, Ferreira J et al (2008) Botulinum toxin type-B improves sialorrhea and quality of life in Bulbaronset amyotrophic lateral sclerosis. J Neurol 255:545\u2013550","journal-title":"J Neurol"},{"key":"4540_CR15","doi-asserted-by":"crossref","unstructured":"Dekhne A, Goklani HD, Doshi N et al (2023) Effectiveness of botulinum toxin in the treatment of neuropathic pain: a literature review. Cureus 15","DOI":"10.7759\/cureus.46848"},{"key":"4540_CR16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s13555-024-01113-3","volume":"14","author":"T Eilertsen","year":"2024","unstructured":"Eilertsen T, Kvammen B\u00d8, Grimstad \u00d8 (2024) Botulinum toxin A and B for palmoplantar hyperhidrosis. Dermatol Ther (Heidelb) 14:805\u2013811","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4540_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000245","volume":"4","author":"A Fischer","year":"2008","unstructured":"Fischer A, Mushrush DJ, Lacy DB, Montal M (2008) Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4:e1000245","journal-title":"PLoS Pathog"},{"key":"4540_CR18","doi-asserted-by":"crossref","first-page":"18098","DOI":"10.1073\/pnas.1908051116","volume":"116","author":"A Flores","year":"2019","unstructured":"Flores A, Ramirez-Franco J, Desplantes R et al (2019) Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B. Proc Natl Acad Sci U S A 116:18098\u201318108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4540_CR19","doi-asserted-by":"crossref","unstructured":"Frucht SJ, Termsarasab P (2024) Pharmacotherapy and botulinum toxin injection: practical advice. Movement disorders phenomenology: therapy and Management, volume II. Springer, pp 787\u2013799","DOI":"10.1007\/978-3-031-52573-5_16"},{"key":"4540_CR20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/1873-3468.14576","volume":"597","author":"L Gao","year":"2023","unstructured":"Gao L, Lam K, Liu S et al (2023) Crystal structures of OrfX1, OrfX2 and the OrfX1\u2013OrfX3 complex from the OrfX gene cluster of botulinum neurotoxin E1. FEBS Lett 597:524\u2013537","journal-title":"FEBS Lett"},{"key":"4540_CR21","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15020092","volume":"15","author":"KS Gregory","year":"2023","unstructured":"Gregory KS, Acharya KR (2023) A comprehensive structural analysis of Clostridium botulinum neurotoxin a cell-binding domain from different subtypes. Toxins (Basel) 15:92","journal-title":"Toxins (Basel)"},{"key":"4540_CR22","doi-asserted-by":"crossref","DOI":"10.3390\/d15030392","volume":"15","author":"T Grenda","year":"2023","unstructured":"Grenda T, Jarosz A, Sapa\u0142a M et al (2023) Molecular diversity of BoNT-producing clostridia\u2014a still-emerging and challenging problem. Diversity 15:392","journal-title":"Diversity"},{"key":"4540_CR23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","volume":"21","author":"\u00d8 Grimstad","year":"2020","unstructured":"Grimstad \u00d8, Kvammen B\u00d8, Swartling C (2020) Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study. Am J Clin Dermatol 21:741\u2013748","journal-title":"Am J Clin Dermatol"},{"key":"4540_CR24","doi-asserted-by":"crossref","unstructured":"Gu S, Jin R (2012) Assembly and function of the botulinum neurotoxin progenitor complex. Botulinum Neurotoxins 21\u201344","DOI":"10.1007\/978-3-642-33570-9_2"},{"key":"4540_CR25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","volume":"77","author":"SH Isaacson","year":"2020","unstructured":"Isaacson SH, Ondo W, Jackson CE et al (2020) Safety and efficacy of RimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol 77:461\u2013469","journal-title":"JAMA Neurol"},{"key":"4540_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2025.108237","author":"B Jabbari","year":"2025","unstructured":"Jabbari B, Tohidian A (2025) An update on botulinum toxin treatment of painful diabetic neuropathy, post-traumatic painful neuropathy\/neuralgia, post-herpetic neuralgia and occipital neuralgia. Toxicon. https:\/\/doi.org\/10.1016\/j.toxicon.2025.108237","journal-title":"Toxicon"},{"key":"4540_CR27","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2023.107264","volume":"234","author":"R Kaji","year":"2023","unstructured":"Kaji R (2023) A look at the future\u2014new BoNTs and delivery systems in development: what it could mean in the clinic. Toxicon 234:107264","journal-title":"Toxicon"},{"key":"4540_CR28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.785600","volume":"193","author":"ING Kao","year":"1976","unstructured":"Kao ING, Drachman DB, Price DL (1976) Botulinum toxin: mechanism of presynaptic blockade. Science 193:1256\u20131258","journal-title":"Science"},{"key":"4540_CR29","volume":"9","author":"YS Kim","year":"2017","unstructured":"Kim YS, Hong ES, Kim HS (2017) Botulinum toxin in the field of dermatology: novel indications. Toxins (Basel) 9:403","journal-title":"Toxins (Basel)"},{"key":"4540_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nsb879","volume":"10","author":"LK Koriazova","year":"2003","unstructured":"Koriazova LK, Montal M (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13\u201318","journal-title":"Nat Struct Biol"},{"key":"4540_CR31","volume":"26","author":"R Kumar","year":"2025","unstructured":"Kumar R, Singh BR (2025) Botulinum toxin: a comprehensive review of its molecular architecture and mechanistic action. Int J Mol Sci 26:777","journal-title":"Int J Mol Sci"},{"key":"4540_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00415-009-0085-1","volume":"256","author":"G Lagalla","year":"2009","unstructured":"Lagalla G, Millevolte M, Capecci M et al (2009) Long-lasting benefits of botulinum toxin type B in parkinson\u2019s disease-related drooling. J Neurol 256:563\u2013567","journal-title":"J Neurol"},{"key":"4540_CR33","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/toxins2050978","volume":"2","author":"FJ Lebeda","year":"2010","unstructured":"Lebeda FJ, Cer RZ, Mudunuri U et al (2010) The zinc-dependent protease activity of the botulinum neurotoxins. Toxins (Basel) 2:978\u2013997","journal-title":"Toxins (Basel)"},{"key":"4540_CR34","volume":"14","author":"KWA Lee","year":"2024","unstructured":"Lee KWA, Chan LKW, Lee AWK et al (2024) Immunogenicity of botulinum toxin type A in different clinical and cosmetic treatment, a literature review. Life 14:1217","journal-title":"Life"},{"key":"4540_CR35","doi-asserted-by":"crossref","DOI":"10.3390\/toxins16030153","volume":"16","author":"L Lippi","year":"2024","unstructured":"Lippi L, de Sire A, Turco A et al (2024) Botulinum toxin for pain relief in cancer patients: a systematic review of randomized controlled trials. Toxins (Basel) 16:153","journal-title":"Toxins (Basel)"},{"key":"4540_CR36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737175.2024.2307490","volume":"24","author":"G Lolascon","year":"2024","unstructured":"Lolascon G, Snichelotto F, Moretti A (2024) An update on the pharmacotherapeutic options for complex regional pain syndrome. Expert Rev Neurother 24:177\u2013190","journal-title":"Expert Rev Neurother"},{"issue":"24","key":"4540_CR37","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1128\/AEM.02428-12","volume":"78","author":"C L\u00faquez","year":"2012","unstructured":"L\u00faquez C, Raphael BH, Joseph LA et al (2012) Genetic diversity among Clostridium botulinum strains harboring bont\/A2 and bont\/A3 genes. Appl Environ Microbiol 78(24):8712\u20138718","journal-title":"Appl Environ Microbiol"},{"key":"4540_CR38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tox.2015.07.003","volume":"335","author":"I Matak","year":"2015","unstructured":"Matak I, Lackovi\u0107 Z (2015) Botulinum neurotoxin type A: actions beyond SNAP-25? Toxicology 335:79\u201384","journal-title":"Toxicology"},{"key":"4540_CR39","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2665","author":"S Motegi","year":"2017","unstructured":"Motegi S, Uehara A, Yamada K et al (2017) Efficacy of botulinum toxin B injection for raynaud\u2019s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-2665","journal-title":"Acta Derm Venereol"},{"key":"4540_CR40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/1346-8138.14140","volume":"45","author":"S Motegi","year":"2018","unstructured":"Motegi S, Sekiguchi A, Saito S et al (2018) Successful treatment of Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary. J Dermatol 45:349\u2013352","journal-title":"J Dermatol"},{"key":"4540_CR41","unstructured":"Murat \u00dc (2024) In the F Eld of oral. Dental And Max llofac al Surgery"},{"key":"4540_CR42","volume":"8","author":"VW Nitti","year":"2006","unstructured":"Nitti VW (2006) Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. Rev Urol 8:198","journal-title":"Rev Urol"},{"key":"4540_CR44","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.celrep.2014.08.017","volume":"8","author":"M Pirazzini","year":"2014","unstructured":"Pirazzini M, Zanetti G, Megighian A et al (2014) Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8:1870\u20131878","journal-title":"Cell Rep"},{"key":"4540_CR43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69:200\u2013235","journal-title":"Pharmacol Rev"},{"key":"4540_CR45","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13010001","volume":"13","author":"C Rasetti-Escargueil","year":"2020","unstructured":"Rasetti-Escargueil C, Popoff MR (2020) Engineering botulinum neurotoxins for enhanced therapeutic applications and vaccine development. Toxins (Basel) 13:1","journal-title":"Toxins (Basel)"},{"key":"4540_CR46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006997","volume":"6","author":"B Riegel","year":"2017","unstructured":"Riegel B, Moser DK, Buck HG et al (2017) Self-care for the prevention and management of cardiovascular disease and stroke: a scientific statement for healthcare professionals from the American Heart Association. J Am Heart Assoc 6:e006997","journal-title":"J Am Heart Assoc"},{"key":"4540_CR47","doi-asserted-by":"crossref","unstructured":"Rummel A (2012) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Botulinum neurotoxins. Springer, pp 61\u201390","DOI":"10.1007\/978-3-642-33570-9_4"},{"key":"4540_CR48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1073\/pnas.0609713104","volume":"104","author":"A Rummel","year":"2007","unstructured":"Rummel A, Eichner T, Weil T et al (2007) Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 104:359\u2013364","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4540_CR49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.iio.0000167169.48520.13","volume":"45","author":"N Sadick","year":"2005","unstructured":"Sadick N, Sorhaindo L (2005) The cosmetic use of botulinum toxin type B. Int Ophthalmol Clin 45:153\u2013161","journal-title":"Int Ophthalmol Clin"},{"key":"4540_CR50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300157","volume":"19","author":"RS Saini","year":"2024","unstructured":"Saini RS, Ali Abdullah Almoyad M, Binduhayyim RIH et al (2024) The effectiveness of botulinum toxin for temporomandibular disorders: a systematic review and meta-analysis. PLoS One 19:e0300157","journal-title":"PLoS One"},{"key":"4540_CR51","doi-asserted-by":"publisher","DOI":"10.1006\/scel.1994.1028","author":"G Schiavo","year":"1994","unstructured":"Schiavo G, Rossetto O, Montecucco C (1994a) Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol. https:\/\/doi.org\/10.1006\/scel.1994.1028","journal-title":"Semin Cell Biol"},{"key":"4540_CR52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1749-6632.1994.tb26614.x","volume":"710","author":"G Schiavo","year":"1994","unstructured":"Schiavo G, Rossetto O, Benfenati F et al (1994b) Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann N Y Acad Sci 710:65\u201375","journal-title":"Ann N Y Acad Sci"},{"key":"4540_CR53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","volume":"80","author":"G Schiavo","year":"2000","unstructured":"Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717\u2013766","journal-title":"Physiol Rev"},{"key":"4540_CR54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1432-1033.1993.tb18327.x","volume":"217","author":"CC Shone","year":"1993","unstructured":"Shone CC, Quinn CP, Wait R et al (1993) Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform\u20102 by botulinum type B neurotoxin. Eur J Biochem 217:965\u2013971","journal-title":"Eur J Biochem"},{"key":"4540_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3344\/kjp.2011.24.1.1","volume":"24","author":"WS Sim","year":"2011","unstructured":"Sim WS (2011) Application of botulinum toxin in pain management. Korean J Pain 24:1\u20136","journal-title":"Korean J Pain"},{"key":"4540_CR56","volume":"2","author":"TJ Smith","year":"2007","unstructured":"Smith TJ, Hill KK, Foley BT et al (2007) Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT\/A3,\/Ba4 and\/B1 clusters are located within plasmids. PLoS ONE 2:e1271","journal-title":"PLoS ONE"},{"key":"4540_CR57","volume":"15","author":"TJ Smith","year":"2023","unstructured":"Smith TJ, Schill KM, Williamson CHD (2023) Navigating the complexities involving the identification of botulinum neurotoxins (BoNTs) and the taxonomy of BoNT-producing clostridia. Toxins (Basel) 15:545","journal-title":"Toxins (Basel)"},{"key":"4540_CR58","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature08156","volume":"460","author":"A Stein","year":"2009","unstructured":"Stein A, Weber G, Wahl MC, Jahn R (2009) Helical extension of the neuronal SNARE complex into the membrane. Nature 460:525\u2013528","journal-title":"Nature"},{"key":"4540_CR59","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2164-14-333","volume":"14","author":"SC Stringer","year":"2013","unstructured":"Stringer SC, Carter AT, Webb MD et al (2013) Genomic and physiological variability within group II (non-proteolytic) Clostridium botulinum. BMC Genomics 14:333","journal-title":"BMC Genomics"},{"key":"4540_CR60","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/mr.44.3.419-448.1980","volume":"44","author":"H Sugiyama","year":"1980","unstructured":"Sugiyama H (1980) Clostridium botulinum neurotoxin. Microbiol Rev 44:419\u2013448","journal-title":"Microbiol Rev"},{"key":"4540_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-025-04909-6","author":"J Sun","year":"2025","unstructured":"Sun J, Chen S, Yang T et al (2025) Efficacy and safety of botulinum toxin type A in primary axillary hyperhidrosis: a meta-analysis and systematic review. Aesthet Plast Surg (17):9. https:\/\/doi.org\/10.1007\/s00266-025-04909-6","journal-title":"Aesthet Plast Surg"},{"key":"4540_CR62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/26412","volume":"395","author":"RB Sutton","year":"1998","unstructured":"Sutton RB, Fasshauer D, Jahn R, Brunger AT (1998) Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 \u00c5 resolution. Nature 395:347\u2013353","journal-title":"Nature"},{"key":"4540_CR63","doi-asserted-by":"crossref","unstructured":"Van Ermengem E (1897) Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Veit","DOI":"10.1007\/BF02220526"},{"key":"4540_CR64","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang K, Ben X et al (2025) Engineered exosomes complexed with botulinum toxin type A for enhanced anti-aging effects on skin. Biology 14:1040","journal-title":"Biology"},{"key":"4540_CR65","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/pme.12017","volume":"14","author":"L Xiao","year":"2013","unstructured":"Xiao L, Cheng J, Zhuang Y et al (2013) Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med 14:276\u2013286","journal-title":"Pain Med"},{"key":"4540_CR66","doi-asserted-by":"crossref","unstructured":"Yamauchi PS (2010) Selection and preference for botulinum toxins in the management of Photoaging and facial lines: patient and physician considerations. Patient Prefer Adherence 345\u2013354","DOI":"10.2147\/PPA.S6494"},{"key":"4540_CR67","volume":"2022","author":"Z Zhang","year":"2022","unstructured":"Zhang Z (2022) Clinical observation of botulinum toxin injection in the treatment of focal dystonia and muscle spasm. Biomed Res Int 2022:1495807","journal-title":"Biomed Res Int"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04540-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04540-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04540-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:07:22Z","timestamp":1771272442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04540-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4540"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04540-8","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}